|Mr. Gaurav Shah||CEO, Pres & Director||N/A||N/A||1975|
|Mr. John C. Militello||Principal Financial & Accounting Officer and Controller||N/A||N/A||1973|
|Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA||COO & Exec. VP of Devel.||N/A||N/A||1979|
|Dr. Claudine Prowse Ph.D.||Sr. VP of Corp. Strategy & IRO||N/A||N/A||N/A|
|Mr. Jonathan Schwartz||Chief Medical Officer & Sr. VP of Clinical Devel.||N/A||N/A||1964|
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Rocket Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 6; Compensation: 8.